Recent News

• 06.06.2025 - Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
• 06.06.2025 - Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
• 06.03.2025 - Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program
• 06.03.2025 - Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program
• 05.29.2025 - Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
• 05.29.2025 - Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
• 05.28.2025 - Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
• 05.28.2025 - Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
• 05.28.2025 - Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102

Recent Filings

• 06.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.03.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 06.03.2025 - 8-K Current report
• 06.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.29.2025 - 8-K/A Current report
• 05.29.2025 - 8-K Current report
• 05.29.2025 - EX-99.1 EX-99.1